Sometimes even the most powerful rockets do not reach the stars.

After seven years of tireless efforts with a stellar and dedicated team of lab scientists, bioinformaticians, and sales specialists supported by a constellation of bright advisors and collaborators, we have unfortunately encountered challenges that we cannot overcome and must announce that the Scipio adventure is coming to an end.

To our customers, thank you for your trust, loyalty, for allowing us to serve you while adopting our single-cell RNA-seq benchtop kit Asteria and its companion data analysis software Cytonaut.

Our aim was for our RevGel technology to be a catalyzer for novel discoveries and improve patients’ lives along the way.

We would also like to thank our past team members, as well as our supporting investors (Merck Ventures, Seventure with the Quadrivium I fund, HTGF, Arbevel, Verve ventures, European Investment Bank and the European Innovation Council with the EIC Accelerator fund), who contributed to the Scipio adventure from its infancy bringing an innovative technological concept into a real application. This journey would not have been possible without you.

We would also like to wish the best success to our colleagues and competitors in the exciting field of single-cell innovation and discoveries. We are all part of the bigger picture that is scientific progress, and each of us propels the others forward.

The start-up adventure can be humbling but we remain convinced that each of us will continue building our scientific understanding and propose innovations for the greater good.

See you for the next challenge!

The Scipio Team

Note: If you think you might need the skillsets from our various team members, please reach out to them directly.